Earnings Releases·Nov 13, 2026, 8:05 AM ET

PAVmed — Third Quarter 2026 Earnings Summary

Revenue surged to $41,000 for the three months ended September 30, 2026, from $5,000 in the prior year period, while the nine-month total reached $96,000 compared to $19,000; however, net loss widened to $11.7 million for the quarter and $17.1 million for the nine months, reversing a $1.7 million net income from the same period in 2025.
Lucid Diagnostics secured a critical milestone by commencing Medicare payments for the EsoGuard test in October 2026, generating $1.2 million in Q3 revenue and achieving record test volumes exceeding 1,800 in October.
Development progress advanced across the portfolio, including a design freeze and initiation of a 90-day animal study for Veris Health's implantable monitor targeting an early 2027 FDA submission, alongside Octeris completing its next-generation probe and PortIO holding an initial FDA meeting.
Cash and cash equivalents increased to $8.9 million as of September 30, 2026, from $1.5 million at the end of 2025, despite operating expenses rising to $6.8 million for the quarter and $21.9 million for the nine-month period.